Industry news
-
Export Potential of Russian Pharmaceuticals
20 June 2019
At this year’s Saint Petersburg International Economic Forum, special consideration is given to the topics of pharmaceuticals, medicine, and healthcare. As one of the key objectives set by Pharma 2030 concerns product export in this field, stakeholders from regulatory authorities, industry associations and the largest exporters held a session meant to identify the forward-looking growth points.
-
Emerging Biopharma’s Contribution to Innovation
19 June 2019
Emerging biopharma (EBP) is a segment of companies driving a large portion of innovation and development in the life sciences. EBP companies are defined as having less than $200 million in estimated annual spending on R&D, or under $500 million in global revenue. EBP’s encompass 3,212 companies in 2018 and account for 73% of late-stage research, up from 52% in 2003, and the number of molecules under development by EBPs grew by 15% in each of the past two years.
-
Industry Publishes a Guide for Companies Working with Patients
19 June 2019
The Association of the British Pharmaceutical Industry (ABPI) has published a guide for pharmaceutical companies on how to work successfully, collaboratively, and ethically with patients and patient groups, in line with the ABPI Code of Practice.
-
Pfizer, ‘never say never’ with big M&A, inks $11.4B Array cancer deal
18 June 2019
Three years after purchasing Medivation for $14.3 billion, Pfizer is back with another hefty M&A deal. And once again, it's betting on oncology. In the first big M&A deal under new CEO Albert Bourla, Pfizer has agreed to buy oncology specialist Array BioPharma for a total value of about $11.4 billion, the two companies unveiled Monday. The $48-per-share offer represents a premium of about 62% to Array stock’s closing price on Friday.
-
Pharma Cluster in Kaluga Region Posts Ten-Fold Revenue Growth in 2012-18
17 June 2019
The pharmaceutical cluster in the Kaluga region saw its revenue grow ten-fold since 2012 to 50 billion rubles in 2018. The cluster employs 10,000 personnel. It encompasses effective industrial infrastructure and specialized engineering centers with a dual system of training personnel, training programs authored by pharmaceutical companies, as well as associated production facilities, the regional government’s press service reported, citing the region’s top economic development official Ilya Veselov.
-
Pharma Cluster in Kaluga Region Posts Ten-Fold Revenue Growth in 2012-18
17 June 2019
The pharmaceutical cluster in the Kaluga region saw its revenue grow ten-fold since 2012 to 50 billion rubles in 2018. The cluster employs 10,000 personnel. It encompasses effective industrial infrastructure and specialized engineering centers with a dual system of training personnel, training programs authored by pharmaceutical companies, as well as associated production facilities, the regional government’s press service reported, citing the region’s top economic development official Ilya Veselov.
-
Russia Established Life-Saving Drugs Price Control Order
14 June 2019
A bill establishing a procedure for regulation of prices for vital and essential medicines has become law. A version of the document signed by Russian President Vladimir Putin has been published on the official website of legal information.
-
Pfizer's Xeljanz matches immunosuppressant combo in rheumatoid arthritis study
14 June 2019
Pfizer’s troubled JAK inhibitor Xeljanz has had its share of hiccups after pulmonary embolism fears derailed the drug’s higher dose in rheumatoid arthritis. Now, Pfizer is hoping for better results using Xeljanz to treat RA patients who wean off immunosuppressants.
-
Luxembourg and the Netherlands Added to EU–US Inspections Agreement
13 June 2019
The two countries have been included into the mutual recognition agreement between the European Union and the US FDA that recognizes facility inspections conducted in different territories. The European Medicines Agency (EMA) announced on June 10, 2019 that Luxembourg and the Netherlands have been included into the mutual recognition agreement between the European Union and the US FDA that mutually recognizes good manufacturing practice (GMP) inspections of manufacturing facilities by other territories. -
State Duma Adopted Bill on Price for VED
13 June 2019
The State Duma adopted a bill to control the prices of vital and essential medicines in a final third reading, according to the information published on the website of the lower house of Russian parliament.
